Immunotherapeutic effect of MIP vaccine along with multidrug therapy (MDT) in leprosy: A systematic review and meta-analysis.

Indian J Med ResSep 1, 2026
Clinical ResearchInfectious DiseasesOpen access

Madhumathi Jayaprakasam, Jigisha Chaudhary, Deenadayalan Boopalan et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of the MIP vaccine as an immunotherapeutic agent in conjunction with standard chemotherapy for multi-bacillary (MB) and pauci-bacillary (PB) leprosy patients. The analysis of four RCTs indicated a significant reduction in clinical scores, with a mean difference of -1.35 at 12 months and -2.62 at 24 months.

Key findings

  • Pooled analysis of four RCTs showed a mean difference in clinical scores of -1.35 at 12 months.
  • At 24 months, the mean difference in clinical scores was -2.62.
  • Non-RCTs indicated a mean difference of -2.97 at 12 months and -3.10 at 24 months.
  • The MIP vaccine was reported to be safe and well-tolerated.

Why it matters

The findings support the use of the MIP vaccine as an adjunct to standard chemotherapy in leprosy, potentially leading to faster bacterial clearance and improved clinical outcomes, which is crucial for managing this neglected tropical disease.

Source

PubMed · PMID 42690855Free full text on PubMed Central

Published in Indian J Med Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.